
Veracyte (VCYT) Stock Forecast & Price Target
Veracyte (VCYT) Analyst Ratings
Bulls say
Veracyte Inc. reported significant growth in genomic test volume, achieving 39,107 tests, which reflects a 25% increase from the previous quarter, supported by an impressive 45% jump in urology tests from the Decipher platform. The company saw a strong performance in adjusted EBITDA, with margins increasing by 690 basis points year-over-year, and testing revenue hitting $112.2 million, marking a 24% rise in the fourth quarter. Furthermore, the revenue from Bethesda V and VI nodules surged over 80% year-over-year, bolstered by increased adoption and a positive outlook on the company's new products, indicating sustained operational momentum and potential for continued financial improvement in 2025.
Bears say
Veracyte Inc. faces a challenging outlook primarily due to slowing revenue growth, which decelerated from 29% in 3Q24 to 21% in 4Q24, driven by underperformance in key products like Afirma and Decipher tests alongside declines in the Biopharma and Product segments. Additionally, the revenue per test has shown a slight decline, dipping approximately 1% from the previous year, raising concerns about the sustainability of revenue levels moving forward. The company also risks facing hurdles related to physician adoption of new diagnostic tests and potential delays in obtaining insurer coverage, which could further complicate financial prospects.
This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.
Veracyte (VCYT) Analyst Forecast & Price Prediction
Start investing in Veracyte (VCYT)
Order type
Buy in
Order amount
Est. shares
0 shares